← Back to catalogue

HemosIL Apixaban Controls

FDA UDIEUDAMED

Class II (US FDA UDI)

by Instrumentation Laboratory Company

Identity

Trade Name
HemosIL Apixaban Controls FDA UDI
Generic Name
Coagulation factor Xa inhibitor IVD, control FDA UDI
Device Name
HemosIL Apixaban Controls kit consists of: 1. Apixaban Low Control (Cat. No. 0020015310): 5 x 1 mL vials 2. Apixaban High Control (Cat. No. 0020015320): 5 x 1 mL vials FDA UDI
Model / Reference
0020015300 FDA UDI
Description
HemosIL Apixaban Controls kit consists of: 1. Apixaban Low Control (Cat. No. 0020015310): 5 x 1 mL vials 2. Apixaban High Control (Cat. No. 0020015320): 5 x 1 mL vials FDA UDI

Identifiers

Catalog Number
00020015300 FDA UDI
Primary DI / UDI-DI
00195226000030 FDA UDI
FDA Product Code
GGN FDA UDI
GMDN Term
Coagulation factor Xa inhibitor IVD, control FDA UDI

Classification

Device Class
Class II FDA UDI
Regulation Number
864.5425 FDA UDI
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

No

FDA UDI

Single Use

No

FDA UDI

Implantable

No

FDA UDI

Contains Latex

No

FDA UDI

Prescription Use

Yes

FDA UDI

Over-the-Counter

No

FDA UDI

Convenience Kit

Yes

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

Yes

FDA UDI

Lot / Batch Number

Yes

FDA UDI

Serial Number

No

FDA UDI

Expiration Date

Yes

FDA UDI

Manufacturing Date

No

FDA UDI

Category: Coagulation factor Xa inhibitor IVD, control

HemosIL Apixaban Controls by Instrumentation Laboratory Company — Class II — IVDR, FDA UDI — listed in FDA GUDID, EUDAMED — regulatory data on deviCERTS

Similar devices

Also classified as Coagulation factor Xa inhibitor IVD, control.

Authorization Coverage (2 countries)

Regulatory Authorizations

European Union Unknown

IVDR

United States Pending data

FDA UDI

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Sources (2)

  • FDA UDI 8c327363-5860-4d96-91ad-fba2a4c62c2e 36 fields · synced Jun 18, 2026
  • EUDAMED 1 fields · synced Jun 3, 2026